Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AstraZeneca | 9.57% | $274.05M | £220.41B | 29.45% | 80 Outperform | |
| HSBC Holdings | 8.91% | $255.14M | £205.11B | 49.44% | 80 Outperform | |
| Shell (UK) | 6.70% | $191.85M | £150.06B | 0.57% | 73 Outperform | |
| Rolls-Royce Holdings | 4.57% | $130.87M | £108.65B | 142.15% | 71 Outperform | |
| Unilever | 4.39% | $125.70M | £103.45B | -6.99% | 72 Outperform | |
| British American Tobacco | 3.77% | $107.78M | £88.17B | 36.88% | 71 Outperform | |
| GlaxoSmithKline | 3.36% | $96.13M | £76.08B | 39.76% | 77 Outperform | |
| Rio Tinto | 3.09% | $88.58M | £101.74B | 24.66% | 82 Outperform | |
| Barclays | 2.92% | $83.53M | £67.09B | 87.91% | 78 Outperform | |
| BP p.l.c. | 2.86% | $81.98M | £65.04B | 0.12% | 71 Outperform |